Latest / ESWI Airborne's Podcast / Respiratory Infections and NCDs: Evidence, Mechanisms and Clinical implications
Transcript
- 0:00ESWI Secretariat: Welcome to ESWI Airborne and our special spotlight series on the Interdisciplinary Disease Collaboration on Respiratory Infections and Non-Communicable Diseases, otherwise known as the IDC.
- 0:12ESWI Secretariat: This episode is the first in our series entitled Breath and Beyond, and it is made possible thanks to the kind support of AstraZeneca and Sanofi, Winthrop Industrie.
- 0:45Jane Barratt: My name is Jane Barrett.
- 0:47Jane Barratt: In our earlier discussions, we introduced the rationale for bringing respiratory infections and non-communicable diseases into the same scientific conversation.
- 0:56Jane Barratt: Today we're going to go further.
- 0:58Jane Barratt: For a scientific audience, the harder questions are: what can we say with confidence?
- 1:04Jane Barratt: Where might we be over-interpreting?
- 1:07Jane Barratt: And what evidence is needed to embed respiratory infection prevention in NCD care?
- 1:13Jane Barratt: I have the great pleasure of being joined by two of our IDC co-chairs, Professor Tor Biering-Sørensen, Professor at the University of Copenhagen, whose research includes the Danish studies at the centre of today's discussion, and Dr.
- 1:29Jane Barratt: Marco Goeijenbier, ESWI board member and physician at Spaarne Hospital in the Netherlands, who brings a broader clinical and scientific perspective on respiratory infections and chronic diseases.
- 1:42Jane Barratt: So, welcome.
- 1:43Jane Barratt: I'm really going to start off and ask you about what the evidence really shows?
- 1:50Jane Barratt: So, Tor, let me start with the Danish studies.
- 1:54Jane Barratt: What do the Dan Flu 2 and Dan RSV studies allow us to say with confidence?
- 2:01Jane Barratt: And where are we at risk of overinterpreting the results?
- 2:07Tor Biering-Sørensen: So, first of all, thank you so much, Jane.
- 2:09Tor Biering-Sørensen: It's uh great to be here together with you and Marco.
- 2:13Tor Biering-Sørensen: Um, so the Dan Flu 2 and the Dan RSV trials were the first of its kind, you know, trials designed to assess whether vaccines lower the risk of hard endpoints like being hospitalized.
- 2:29Tor Biering-Sørensen: Remember, you know, the first the phase three trials of vaccines are not powered for hard outcomes, they are powered to assess whether you prevent an infection.
- 2:38Tor Biering-Sørensen: Uh, but these trials were conducted in in such a big size, a large size, that they actually had power to assess whether we also prevent hospitalization events and not only the infection or when having the infection.
- 2:55Tor Biering-Sørensen: So that's that's you know what they would assign to.
- 2:58Tor Biering-Sørensen: And and therefore what we can say with confidence uh based on uh reading out from these trials is that it seems as if we can prevent hospitalizations um with with uh with vaccines for an RSV vaccine specifically.
- 3:15Tor Biering-Sørensen: We know that we can prevent uh RSV uh infection and hospitalizations uh with RSV.
- 3:21Tor Biering-Sørensen: We also know that we can prevent hospitalizations uh that are more broad, so all-cause hospitalization uh events due to respiratory tract disease if we uh vaccinate our elderly with an RSV vaccine.
- 3:34Tor Biering-Sørensen: And this, of course, underscores the fact that RSV is not a disease like flu or COVID that is being uh tested for as broadly since we see that we prevent uh some of the all-cause outcomes, right?
- 3:46Tor Biering-Sørensen: The they're just not being measured.
- 3:48Tor Biering-Sørensen: For Dan Flu 2, it was a uh high-dose flu vaccine versus a standard dose flu vaccine, um, which we compared in a randomized trial of more than 300,000 individuals.
- 3:59Tor Biering-Sørensen: There we saw that the primary endpoint of hospitalizations for phenomena influenza wasn't actually significant, so we didn't reach our primary outcome.
- 4:08Tor Biering-Sørensen: But we saw a very big effect on hospitalizations for flu specifically, uh, a relative risk reduction of close to 40%, which is much, much greater than what we expected, you know, when we know that that the relative risk for getting flu with a high dose versus standard dose flu vaccine from the phase three trial was only 25% lower risk of having flu.
- 4:31Tor Biering-Sørensen: So this actually translates into a potentially greater risk of of uh preventing flu hospitalization specifically.
- 4:38Tor Biering-Sørensen: So if we look into these uh non-communicable diseases specifically, which we discussed so much, none of the trials were actually powered for these endpoints, right?
- 4:47Tor Biering-Sørensen: But we see that they have a much higher baseline risk.
- 4:51Tor Biering-Sørensen: So people who are diseased, when they are being vaccinated, they have a much greater absolute risk reduction, underscoring the fact that that we can prevent many more hospitalization events uh when when when using vaccines in these specific patient populations.
- 5:08Tor Biering-Sørensen: And I think that is what I would argue we at least can say with confidence based on the randomized evidence.
- 5:16Tor Biering-Sørensen: Vaccines don't only prevent the infection, they also prevent the downstream hospitalization.
- 5:20Tor Biering-Sørensen: But regarding non-accumulable diseases, it's mainly that we uh we prevent more absolute hospitalization events because they have a greater or higher baseline risk.
- 5:31Tor Biering-Sørensen: So that would be my my interpretation uh uh and and and and you know trying not to overinterpret uh these findings from these specific trials.
- 5:42Jane Barratt: Look, that's that's very impressive, Tor.
- 5:44Jane Barratt: I'm gonna turn to Marco now.
- 5:46Jane Barratt: Marco, you're on the front line.
- 5:48Jane Barratt: So, you know, with your with your you know clinical perspective and a broader scientific perspective, where is the respiratory infection and NCD relationship best established?
- 6:00Jane Barratt: And where does it remain more speculative from your put your point of view?
- 6:05Marco Goeijenbier: Thank you, Jane, and always a pleasure to discuss uh these kind of topics with you and with Tor.
- 6:10Marco Goeijenbier: Um and this is a this is a good question to uh to actually start with, uh, because of course we do know that from disease X uh uh you have a higher chance of of developing more severe respiratory outcome of specific respiratory infections.
- 6:24Marco Goeijenbier: So we do know that that certain chronic diseases predispose to a more clinic, a severe clinical course of infections.
- 6:31Marco Goeijenbier: But it's the other way around now where we where we should actually gather more and more evidence.
- 6:35Marco Goeijenbier: So I think the link is real, but it's not uniform.
- 6:38Marco Goeijenbier: Uh so we need to define it by pathogen, by patient group, and by clinical outcome, but also really understand uh the mechanism behind it.
- 6:45Marco Goeijenbier: Um so I think now uh uh really linking uh non-communical diseases uh towards uh respiratory infections, uh the the best evidence comes, of course, from from uh the the occurrence of the increased occurrence of cardiovascular events uh uh after a couple of weeks of a respiratory infection.
- 7:03Marco Goeijenbier: That link is quite clear, but we absolutely do not understand why this occurs.
- 7:08Marco Goeijenbier: So is it is it the virus itself?
- 7:09Marco Goeijenbier: Is it systemic inflammation?
- 7:11Marco Goeijenbier: Uh is it only in specific risk patients and are we actually doing a stress test with a with a with a more severe infection?
- 7:18Marco Goeijenbier: Um so I think the uh the studies that are coming out now, or the data that has been gathered the past years show that that by vaccinating you reduce reduce the the burden of these non-communical diseases on healthcare.
- 7:31Marco Goeijenbier: But but why and how we don't understand yet.
- 7:34Marco Goeijenbier: Um so my view is well, well, the concept is starting to get established, but the size of the effect, the pathogen-specific mechanisms, the best endpoints for prevention, those are still area areas where the science really needs to mature.
- 7:48Jane Barratt: You know, it really feels as though we're sort of on the edge of some major, you know, um major um results that are going to theoretically, you know, change the way we see practice in the future.
- 8:03Jane Barratt: And so I I want to turn turn to you again, Tor, and talk about the Dan Flu 2 study.
- 8:08Jane Barratt: Um Marco mentioned, you know, the importance of the cardiovascular outcomes, but what was the strongest cardiovascular signal and and how should a cautious scientist interpret it?
- 8:22Jane Barratt: Now you're both, aren't you?
- 8:23Jane Barratt: You're a scientist and a clinician.
- 8:25Jane Barratt: So, you know, with your scientist hat, um how are you interpreting this?
- 8:31Tor Biering-Sørensen: No, that's that's a great question, and I um I can only uh echo uh what Marco just mentioned, you know, that over the last um uh at least two decades we have seen this uh this increased risk of cardiovascular outcomes, uh also temporarily um associated with uh respiratory tract infections, and that has been mainly ischemic events that that those studies uh have been been focused on.
- 9:00Tor Biering-Sørensen: Very interestingly, in in Danflu II and also fluunity HD, which was the combination of DanFlu and Galflu, which were two trials that were were uh conducted with the same protocol with the pre-specified intention to pool those two data sets.
- 9:18Tor Biering-Sørensen: We saw that the greatest uh uh the or the the greatest risk uh lowering effects of a high dose flu vaccine versus a standard dose flu vaccine, which we know prevents flu and which we know are very um very useful in in preventing uh inf uh influenza infections, we saw the greatest risk reduction uh in heart failure hospitalization.
- 9:41Tor Biering-Sørensen: Um and that was uh I think prior prior to our uh initiating the studies, not the cardiovascular outcome, which I at least expected.
- 9:50Tor Biering-Sørensen: I had done a lot of of observation data or studies using self-control case series analysis, looking at these uh temporal associations, and that was my cardiinfarction or stroke.
- 10:02Tor Biering-Sørensen: But it seems as if we are potentially preventing heart failure hospitalization in a greater magnitude than at least these ischemic events.
- 10:12Tor Biering-Sørensen: And that that's very, very interesting and a new eye-opening uh experience, at least for me.
- 10:18Tor Biering-Sørensen: And remember, I'm a cardiologist and I'm a heart failure cardiologist specifically.
- 10:23Tor Biering-Sørensen: So I was you know extremely excited to see this 20% relative risk reduction of heart failure hospitalization, which we experienced in Danflu, in Galfu and Influnity.
- 10:34Tor Biering-Sørensen: Um so it has opened a whole new way of thinking, and and maybe we should focus more on heart failure than the ischemic events uh when when when talking about respiratory trait uh diseases.
- 10:47Jane Barratt: You know, both of you are really disgusting about the reduction in hospitalizations, and with that is the reduction on the health dollar.
- 10:55Jane Barratt: So these results are really benchmark in policy development also.
- 11:02Jane Barratt: I wish I wish our audience could see both of you because you're nodding in agreement each time one of you, you know, responds to a question.
- 11:12Jane Barratt: Um, Marco, from a clinical perspective though, you know, what is the most convincing pathway linking respiratory infection to cardiovascular decompensation?
- 11:23Marco Goeijenbier: That's another great question.
- 11:24Marco Goeijenbier: Uh so uh for me, the the most convincing pathway, it's it's not a single mechanism.
- 11:29Marco Goeijenbier: Uh I tried to study it during my PhD looking into ferrets uh who got influenza, see what happened there.
- 11:34Marco Goeijenbier: But it's a combination of several mechanisms all happening at the same time in a patient with limited reserve, as Thor already discussed.
- 11:42Marco Goeijenbier: So during or after respiratory infection, you see systemic inflammation, uh, you get an endothelial cell response, so the inner vascular the inner layer of your vasculature will will respond.
- 11:51Marco Goeijenbier: You actually move towards a pro-trombotic state.
- 11:54Marco Goeijenbier: Uh at the same time, due to the underlying disease, a patient can become hypoxic, tachycardia, so heart rhythm goes up, he goes uh the patient can become febrile, and this all increases myocardial oxygen demand uh while oxygen delivery might may be reduced.
- 12:09Marco Goeijenbier: So we're actually looking at this this huge stress test.
- 12:12Marco Goeijenbier: And and maybe in healthy young persons uh you can pass this stress test without any major events, but in those with limited reserve or already underlying cardiac disease, it can be the the the drop that makes the bucket flood, right?
- 12:24Marco Goeijenbier: So so I would describe respiratory infection as a systemic stress test.
- 12:28Marco Goeijenbier: Uh healthy healthy people are okay, but people with NCDs have have much less reserve.
- 12:35Jane Barratt: Look, it it's interesting about this stress test for healthy people, they may manage it.
- 12:41Jane Barratt: But with people that have NCDs or and in the latter half of life, you know, they're really going to struggle with that stress test.
- 12:50Marco Goeijenbier: So there's one interesting point during the the the first wave of uh of of COVID.
- 12:55Marco Goeijenbier: Um so so when there was absolutely no uh predisposing immunity, you you did see uh cardiac ischemia in in relatively healthy people.
- 13:02Marco Goeijenbier: So but that's because then the virus got so big.
- 13:05Marco Goeijenbier: Uh so it's it's continuously uh a balance between uh the pathogen on one side and the host or the patient at the other.
- 13:12Jane Barratt: It's beautiful the way that you talk about it.
- 13:14Jane Barratt: You know, the pathogen and the you know, it's it's this balance that you're all that the body is always trying to attain, isn't it?
- 13:22Jane Barratt: Um Tor, you've talked a little bit about heart failure, but I want to go back to it and and with a particular emphasis.
- 13:30Jane Barratt: So is the heart failure signal biologically plausible, clinically meaningful, and strong enough to shape future vaccine studies?
- 13:40Jane Barratt: Um what do you think from your work?
- 13:44Tor Biering-Sørensen: Yes, I I think you know it's you know, when when thinking about it, you know, we we've had since this association, which um uh Mar Marco also um mentioned about all of these cardiovascular outcomes, and and there's been a lot of research on this specific topic, um, where there's come up a lot of hypotheses about whether you know you're uh stabilizing uh or making a plaque unstable if you have an infection.
- 14:14Tor Biering-Sørensen: There's been a lot of hypothet hypothesis about you know the mechanisms.
- 14:18Tor Biering-Sørensen: I don't really understand it.
- 14:20Tor Biering-Sørensen: Well in heart failure, I think it's probably much it's much more easy to understand.
- 14:26Tor Biering-Sørensen: Remember, now we had the trial, we've seen the effect, so now we know that them there must be some kind of causal uh relationship between preventing flu and then preventing heart failure hospitalizations, right?
- 14:39Tor Biering-Sørensen: Because it's from randomized evidence that we have seen these uh these results.
- 14:44Tor Biering-Sørensen: Of course, the trials haven't been powered specifically for the heart failure endpoints, and that has to be underscore.
- 14:50Tor Biering-Sørensen: So it is still hypothesis generating.
- 14:52Tor Biering-Sørensen: But understanding that you know the main symptom in heart failure, that's diphnia, right?
- 14:58Tor Biering-Sørensen: So it's it's an increase uh in the pressure uh in the lungs, in the vessels in the lungs.
- 15:05Tor Biering-Sørensen: Where is it that this these respiratory infections they uh they infect?
- 15:11Tor Biering-Sørensen: And I know Marco knows much more about this in detail, but it's the lungs as well, right?
- 15:16Tor Biering-Sørensen: And and is the the thing that we see in our heart failure patients when they're hospitalized for acute heart failure, that is uh is fluid in the lungs.
- 15:25Tor Biering-Sørensen: And infection does also make you know the lung permeability of the vessel um higher, so you also have a greater um greater um uh risk of having fluid in the lungs, right?
- 15:40Tor Biering-Sørensen: So the heart and and these infections are actually uh leading to or um or attacking the same system and creating the perfect storm for for having fluid in the lungs, right?
- 15:56Tor Biering-Sørensen: So I think that's at least that's been my uh my uh way of thinking that people who are already in risk of having heart failure that haven't been pushed over the border, if they get an infection, you know, the permeability of the blood vessels in the lung might get more permeable, and thereby the higher pressure that you see in the vessels that they already have uh leads to fluid in the lungs, which is the cardinal symptom in our heart failure patients.
- 16:26Tor Biering-Sørensen: So I think uh it makes sense probably also much more than all the other theories that we've had with with the mechanisms of how a flu, R C V COVID potentially causes myocardial infarctions, uh strokes, and so on.
- 16:41Tor Biering-Sørensen: Um but but I know that that Marco, he is a greater specialist in this than I than I am.
- 16:46Tor Biering-Sørensen: So so that's at least been my you know um my way of thinking.
- 16:51Tor Biering-Sørensen: But this is of course after I know the results, right?
- 16:54Tor Biering-Sørensen: And after I this link.
- 16:56Jane Barratt: So yeah.
- 16:56Jane Barratt: Look, I I think that's a very comprehensive kind of position.
- 17:01Jane Barratt: But I do want to actually challenge Marco a little bit more on how the science should be changing now.
- 17:08Jane Barratt: Um it seems to me that, you know, the Dan studies have really pushed us to look at bi-directional relationships.
- 17:16Jane Barratt: And uh Marco, I just want to ask you, are we still too pathogen-centered in the way we study respiratory infections?
- 17:26Jane Barratt: You know, should we be moving more to a patient-centered model?
- 17:31Jane Barratt: And what would change scientifically?
- 17:33Jane Barratt: I know it's a it's a it's a broad question, but it's a question that's important.
- 17:38Marco Goeijenbier: Yeah, it's it's definitely a broad question.
- 17:40Marco Goeijenbier: Um just to quickly get back to Tor, I think you're getting quite a specialist yourself there on this point here, because that's just an excellent answer.
- 17:48Marco Goeijenbier: I wouldn't add anything there.
- 17:49Marco Goeijenbier: Uh, but do yeah, I do think we are still quite pathogen centered.
- 17:54Marco Goeijenbier: Uh quite uh for every pathogen and every vaccine available, there needs to be one specific trial.
- 17:59Marco Goeijenbier: So we often design studies around whether we prevent influenza, we prevent RSV, we pre we prevent SARS-CoV-2, and that's the virological endpoint.
- 18:06Marco Goeijenbier: That's important.
- 18:07Marco Goeijenbier: But for many patients and especially clinicians, the real question is different.
- 18:11Marco Goeijenbier: Does prevention reduce hospitalization?
- 18:13Marco Goeijenbier: Does it reduce decompensation?
- 18:15Marco Goeijenbier: Does it reduce exacerbation of COPD?
- 18:18Marco Goeijenbier: And then when you focus on one specific pathogen and you put a lot of money and a lot of effort in it, but you forget about the others, then the patient might just as well be very, very, very well uh protected against influenza, but gets an RSV infection or uh a SARS-CoV-2 infection, and with the same uh systemic inflammatory response, the same pro-cagoline response and the same um uh uh the same outcomes.
- 18:40Marco Goeijenbier: But then so so I think first the the endpoints need to become clinically very meaningful, but that that's happening now.
- 18:47Marco Goeijenbier: So so the Tor is doing a great job there.
- 18:49Marco Goeijenbier: Uh it's not only laboratory-confirmed infection, but it's it should focus on hospitalization.
- 18:54Marco Goeijenbier: And that's that's a whole other uh subject, and we can make multiple podcasts about it, but but the the the burden on on hospital care uh is a is a big problem, especially with aging uh society.
- 19:05Marco Goeijenbier: Uh so we have uh less and less people actually willing to work in healthcare, and we've got more and more patients there.
- 19:11Marco Goeijenbier: So anything that that can reduce the burden on hospital uh capacity is very, very important.
- 19:17Marco Goeijenbier: But then also, secondly, in these studies, population should be selected based on on vulnerability.
- 19:22Marco Goeijenbier: So not only only age, age is useful, but age is very, very crude.
- 19:26Marco Goeijenbier: So we move better better risk stratification, heart failure, COPD, diabetes, frailty.
- 19:31Marco Goeijenbier: Um we had a lovely discussion in in Brussels with with lots of of stakeholders that are really diving into this subject.
- 19:38Marco Goeijenbier: And maybe one of the most important questions is if I prevent uh uh uh uh by any means possible the different respiratory infections, so by uh by an optimized uh vaccination schedule, uh will that that person live longer without any care?
- 19:53Marco Goeijenbier: Uh so so I think those are very, very important questions.
- 19:57Marco Goeijenbier: But then finally, we need to get the right disciplines uh involved from the beginning.
- 20:01Marco Goeijenbier: So you need cardiologists, pulmonologists, geriatrics, primary care, epidemic epidemiology, but also implementation science.
- 20:08Marco Goeijenbier: Uh and this should help define the question from the start.
- 20:12Jane Barratt: Yes.
- 20:12Jane Barratt: Look, I'm just going to come back to you again, Marco, and and ask about evidence threshold and implementation.
- 20:19Jane Barratt: Um because I'm really interested.
- 20:21Jane Barratt: Part of the meeting in Brussels, we talked about vaccination being part of NCD management.
- 20:28Jane Barratt: And you're a clinician at the front lines, you know, right as we speak.
- 20:32Jane Barratt: So, what would convince you that vaccination should be treated not only as an infection prevention, but as part of NCD management?
- 20:41Marco Goeijenbier: Yeah, well, you you made this statement earlier during this podcast that I think we're on the verge of seeing something big, and I absolutely agree there.
- 20:49Marco Goeijenbier: I think we're we're getting there, but we're not there yet.
- 20:52Marco Goeijenbier: Um, so what would make my life easy, because of course I'm I'm a believer, and and I think all the all the evidence is there in different boxes, and we just need to combine them, and we need to combine them and then add uh data from the giga trials that that are that are done now.
- 21:07Marco Goeijenbier: Uh, but it would make my life easier convincing my my co-workers if we see consistent evidence that vaccination reduces clinically meaningful meaningful outcomes in well-defined NCD populations.
- 21:17Marco Goeijenbier: That's what we need.
- 21:18Marco Goeijenbier: Uh and we need it on a large scale.
- 21:20Marco Goeijenbier: Uh, and then we need people to actually help us, so from a completely different field, social sciences, or how we bring this data to policymakers and how we would actually change daily clinical work.
- 21:32Jane Barratt: Yeah, look, I'm not convinced that either of you will have an easier life because it seems to me that both of you are really, you know, stepping into pioneering areas.
- 21:42Jane Barratt: So um, I don't think you've got a chance on that.
- 21:44Jane Barratt: But Tor, one issue that was raised during the IDC meeting and the summit was the difficulty of obtaining grade 1A guideline recommendations.
- 21:55Jane Barratt: And there was quite a debate about this.
- 21:57Jane Barratt: From your perspective, what kind of heaven?
- 21:59Jane Barratt: Would be required to reach that level of recommendation, if at all.
- 22:04Jane Barratt: Because I know that you you had particular views.
- 22:08Tor Biering-Sørensen: No, but but I I I agree completely with Marco again, as you mentioned, Jane, you know, I'm just nodding every time Marco is saying something.
- 22:18Tor Biering-Sørensen: And so I agree completely, you know.
- 22:20Tor Biering-Sørensen: We already know that these vaccines work to prevent uh prevent the diseases they are designed to prevent.
- 22:27Tor Biering-Sørensen: Now, through the GIGA trials that we power to show that they also prevent uh hospitalizations due to these kinds of infections, you know, then we have that additional information.
- 22:39Tor Biering-Sørensen: But the trials that often are discussing these specific topics of non-cumulable diseases are of course not powered to show that a vaccine prevents, you know, a stroke or future myocardial infarction.
- 22:53Tor Biering-Sørensen: And I think I think we have these amazing vaccines and and our all of the guidelines currently recommend them.
- 23:00Tor Biering-Sørensen: But the only thing is if we want to recommend them specifically for preventing non-cumulable diseases, then of course we need the trials that show that that they prevent, you know, uh diabetes, they prevent uh or diabetes hospitalization, they prevent uh acute myocardial infarction, they prevent uh stroke.
- 23:19Tor Biering-Sørensen: We do have some trials within some of these topics.
- 23:22Tor Biering-Sørensen: We actually have it for myocardial infarction, we also have it for heart failure hospitalization.
- 23:26Tor Biering-Sørensen: So some of these trials are being done.
- 23:28Tor Biering-Sørensen: But it's just to say that at least within my field of cardiology, for the great majority of cardiovascular diseases that we have, we don't have these trials.
- 23:38Tor Biering-Sørensen: So we can recommend them to prevent uh flu, prevent RSV, prevent COVID.
- 23:43Tor Biering-Sørensen: We can also now say you can use uh RSV vaccines to prevent hospitation, and you can use the proof flu vaccine to prevent hospitalization due to the pathogens.
- 23:52Tor Biering-Sørensen: But if we need the 1A recommendation, and I'm not sure we need them for any, for all of the diseases, right?
- 23:59Tor Biering-Sørensen: Because it's it's it's a strong enough argument that we prevent, you know, and that's shown in randomized far that we prevent hospitalization due to the disease.
- 24:07Tor Biering-Sørensen: Um but if we if we want to argue that we also prevent these other downstream events, that has become a a very big portion of what we think about when we talk about preventing respiratory infections in in non-cumulative diseases, then of course we would need trials designed to show that specific.
- 24:24Tor Biering-Sørensen: For example, my uh web dream, so to say, is to you know design uh uh a trial to that is powered for heart freed hostilization now and I see that that's a 20% relative risk reduction potentially to gain from preventing uh a flu infection.
- 24:42Tor Biering-Sørensen: So so so that would be amazing.
- 24:44Tor Biering-Sørensen: So we could get get it into the guidelines saying that you know uh you should also get vaccinated because we prevent heart failure, because heart failure is also a disease of the lung, uh long heart infection, of course, just like the respiratory, and you are exaggerating the effect of our respiratory tract infection, right?
- 25:03Tor Biering-Sørensen: But again, it's I know that I'm a radical trialist.
- 25:07Tor Biering-Sørensen: We need the trials if you want the one A recommendation, but I don't think we need the one A recommendation for everything.
- 25:12Tor Biering-Sørensen: You know, we have a lot of evidence that vaccines are amazing to prevent what they're designed to.
- 25:18Tor Biering-Sørensen: The new uh the new part is just you know, all the additional stuff that we are beginning to understand that vaccines actually also prevent.
- 25:27Tor Biering-Sørensen: And I can only underscore again that we also already know now that those who have diseases, chronic diseases, they at baseline are much much higher risk.
- 25:39Tor Biering-Sørensen: We know that also from from all the data.
- 25:42Tor Biering-Sørensen: So vaccinating them, you have a much greater absolute benefit because uh, you know, you prevent many more hospitalization events.
- 25:51Tor Biering-Sørensen: What Mark also underscored this uh risk stratification, not only looking at age, you know, uh uh a 40-year-old uh with diabetes has a much, much greater risk than a healthy 65-year-old, probably.
- 26:04Tor Biering-Sørensen: So so we are also simplifying stuff, or at least trying to simplify things where where we we we're not using the vaccines necessarily to those at greatest uh risk uh always.
- 26:15Tor Biering-Sørensen: But yeah.
- 26:16Jane Barratt: Yeah, Tor, I'm not sure that I would see you as a radical trialist, a positive disruptor, but perhaps not a radical trialist.
- 26:23Jane Barratt: But uh I take it.
- 26:27Marco Goeijenbier: I wouldn't mind this.
- 26:30Jane Barratt: Look, I I think both both of you are uh radical in a positive way.
- 26:34Jane Barratt: How's that?
- 26:35Jane Barratt: Um, I've got one final question for you, and it it really takes us back to the importance of the interdisciplinary disease collaboration on respiratory infections and NCDs.
- 26:48Jane Barratt: You know, anybody listening to this podcast will have no hesitation in understanding the importance of the IDC collaboration.
- 26:58Jane Barratt: Um, you know, you are two of the co-chairs, and and this podcast has been rich in information that really is at the cutting edge.
- 27:07Jane Barratt: And I think the fact that you know you're both clinicians also speaks to how we take evidence into action.
- 27:15Jane Barratt: But this final question, um, and perhaps we start off with Tor.
- 27:19Jane Barratt: Um, what is the one scientific question IDC must answer next, Tor?
- 27:26Tor Biering-Sørensen: Yeah, that's uh a great question, Jane, and and also hard.
- 27:30Tor Biering-Sørensen: It's good that I also have Marco by my side so he also can pitch in.
- 27:34Tor Biering-Sørensen: But um, but I think um the the first thing is just you know following what we just discussed, you know, if if uh uh first of all, bringing all the bright people together in ITC, you know, listening to each other, uh learning from the different specialities, and then also figuring out where is it we need, where is it needed to be implemented.
- 27:59Tor Biering-Sørensen: And it and I think the big uh thing that Mark also mentioned, the implementation gap.
- 28:04Tor Biering-Sørensen: Often we have a lot of knowledge, and for vaccines and for these vaccines, we actually have a lot, lot of information.
- 28:10Tor Biering-Sørensen: So and understanding the implementation gap and where it's needed, where more science is needed is is a very big thing.
- 28:17Tor Biering-Sørensen: And when doing this science, you know, trying to do it randomized if any way possible.
- 28:23Tor Biering-Sørensen: And I think that has been a learning point, at least for me, that within vaccines we can actually do quite innovative large-scale trials.
- 28:30Tor Biering-Sørensen: So if we need it, then let's move ahead and push for our randomized controlled experiments showing that it actually matters when we talk about causal relationships and not just uh associations.
- 28:43Tor Biering-Sørensen: And and then I'll give the floor to Marco.
- 28:46Marco Goeijenbier: I I think that that's an amazing start.
- 28:47Marco Goeijenbier: And then to add on there, the challenge is not not only proving efficacy, but it's then embedding prevention into your route in NCD care.
- 28:54Marco Goeijenbier: And if you're taking it back to clinical implementation, which of course is a very, very important discussion point, uh, we I want to see that vaccination can be embedded in the car uh care pathways, for instance, in in heart failure, in COPD, in diabetes.
- 29:08Marco Goeijenbier: Um I think uh as we are at at the beginning of something big, as we already mentioned a couple of times, I think what what would convince the rest is not a single perfect study, but it's a coherent evidence package.
- 29:21Marco Goeijenbier: We need the biological plausibility, consistent clinical outcome data, and and then eventually, and maybe the biggest challenge, feasibility and routine care.
- 29:30Jane Barratt: Look, thank you very much.
- 29:32Jane Barratt: And and just to make the point that the ESWI IDC is has a unique position in the world when it comes to evidence and clinical practice and policy.
- 29:45Jane Barratt: And so today's discussion has taken us well beyond the claim that respiratory infections and NCDs are connected.
- 29:52Jane Barratt: The harder task, which has been discussed today by Tor and Marco, is to define the strength of that connection, the mechanisms behind it, and the outcomes that matter, as well as the level of evidence needed to change clinical practice.
- 30:08Jane Barratt: And that's why we served up, you know, some challenging questions to these uh scientists and clinicians.
- 30:14Jane Barratt: The Danish studies are so very important, critical in fact, because they have moved the field toward clinically meaningful endpoints.
- 30:24Jane Barratt: But as you can hear from these radical trialists, you know, we need to go further forward.
- 30:30Jane Barratt: They've also raised important questions about interpretation, generalizability, and implementation.
- 30:36Jane Barratt: And this is exactly where IDC has a role to play.
- 30:40Jane Barratt: Now, at this intersection, IDC is not simply raising awareness.
- 30:47Jane Barratt: That's that's part of its job, but it's certainly not its job.
- 30:51Jane Barratt: It is there to sharpen the science, challenge assumptions, and help identify what evidence is needed for respiratory infection prevention to become part of NCD care.
- 31:02Jane Barratt: And what I found most important attending the summit in Brussels was the opportunity to agree and to disagree, you know, to really debate some of the important endpoints.
- 31:14Jane Barratt: My sincere thanks to Dr.
- 31:17Jane Barratt: Goeijenbier and Biering- Sørensen for joining this discussion.
- 31:21Jane Barratt: And thank you very much for listening.
- 31:23Marco Goeijenbier: Thank you very much.
- 31:24Tor Biering-Sørensen: Thank you, Jane.
- 31:30ESWI Secretariat: ESWI Airborne is brought to you by ESWI, the European Scientific Working Group on Influenza and other acute respiratory viruses.
- 31:38ESWI Secretariat: These episodes would not be possible without the team's efforts, and I would like to extend special thanks to our ESWI Secretariat, our technical and IT teams, our arts team, and our host.
- 31:49ESWI Secretariat: The podcasts are recorded virtually, and we thank our guests for their participation in this inspiring and educational series.
- 31:57ESWI Secretariat: Talks are adapted to a global audience and are intended as recommendations and guiding principles.
- 32:04ESWI Secretariat: For any specific medical questions you may have, these should be addressed to your local general practitioner.
- 32:11ESWI Secretariat: Many thanks to our sponsoring partners, and thank you for listening.